ACSL6 Activators are a specific group of chemical compounds that facilitate the enhancement of the functional activity of Acyl-CoA synthetase long-chain family member 6 (ACSL6). ACSL6 is an enzyme that plays a pivotal role in the metabolism of long-chain fatty acids by catalyzing the conversion of these fatty acids into their corresponding acyl-CoA derivatives, which are then primed for subsequent metabolic pathways such as beta-oxidation, lipid synthesis, and signaling lipid production. The chemical compounds that act as ACSL6 Activators achieve this enhancement through various mechanisms, including allosteric modulation, substrate availability alteration, and transcriptional regulation, all of which are integral to maintaining cellular lipid homeostasis.
These activators include compounds that engage with proteins or receptors that directly or indirectly upregulate ACSL6 activity. Compounds like SRT1720, Leptin, and AICAR operate through the activation of proteins such as SIRT1 and AMPK, which promote the post-translational modification of ACSL6, leading to its enhanced activity. These modifications can alter the enzyme's conformation, stability, or interaction with other cellular components, consequently increasing its functionality. Furthermore, the activation of nuclear receptors such as PPARα by specific agonists like GW7647, Bezafibrate, and WY-14643 results in the upregulation of ACSL6 gene expression, leading to an increase in enzyme levels and activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SRT1720 | 1001645-58-4 | sc-364624 sc-364624A | 5 mg 10 mg | $193.00 $357.00 | 13 | |
SRT1720 is a specific activator of SIRT1, which can enhance fatty acid oxidation by deacetylating ACSL6, leading to its activation. SIRT1-mediated deacetylation is known to activate several metabolic enzymes. | ||||||
Ob (hBA-147) | sc-4912 | 1000 µg | $253.00 | 1 | ||
Leptin can enhance fatty acid oxidation through activation of AMPK, which in turn can increase ACSL6 activity, linking hormonal signaling with lipid metabolism. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR activates AMPK, which can then phosphorylate and enhance the activity of ACSL6, thus promoting the utilization of fatty acids. | ||||||
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $30.00 $45.00 $120.00 $200.00 | 5 | |
Bezafibrate is a PPAR pan-agonist that can increase the transcription of ACSL6, among other genes, leading to enhanced fatty acid metabolism. | ||||||
GW 7647 | 265129-71-3 | sc-203068A sc-203068 sc-203068B sc-203068C | 1 mg 5 mg 10 mg 25 mg | $48.00 $167.00 $262.00 $648.00 | 6 | |
GW7647 is a potent PPARα agonist that can upregulate the expression of ACSL6, promoting its activity in lipid metabolism pathways. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
Fenofibrate, through its action as a PPARα agonist, can enhance the expression and activity of ACSL6, thereby increasing fatty acid oxidation. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $133.00 | 7 | |
WY-14643 is a PPARα agonist known to upregulate genes involved in fatty acid metabolism, including ACSL6, thus enhancing its enzymatic activity. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Although primarily a PPARγ agonist, Pioglitazone can also influence PPARα-related pathways, possibly leading to increased ACSL6 activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone is a PPARγ agonist that may have secondary effects on ACSL6 function and expression due to cross-talk between PPARγ and PPARα signaling. | ||||||
Palmitoylethanolamide | 544-31-0 | sc-202754 sc-202754A sc-202754B sc-202754C sc-202754D | 10 mg 50 mg 500 mg 1 g 10 g | $78.00 $238.00 $2050.00 $3274.00 $16330.00 | ||
Palmitoylethanolamide may enhance ACSL6 activity by increasing substrate availability through its actions as an endogenous fatty acid ethanolamide. | ||||||